Enliven Therapeutics (ELVN) EPS (Weighted Average and Diluted) (2021 - 2026)
Enliven Therapeutics' (ELVN) quarterly EPS (Weighted Average and Diluted) came in at -$0.38 in Q1 2026, up 33.33% year-on-year from -$0.29 in Q1 2025, and up 20.83% quarter-over-quarter from -$0.48 in Q4 2025.
Enliven Therapeutics (ELVN) EPS (Weighted Average and Diluted) (2021 - 2026) Analysis & Trends
Enliven Therapeutics has disclosed EPS (Weighted Average and Diluted) across 6 years of filings, most recently posting -$0.38 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.38, up 33.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.67 (up 13.02% YoY), and the FY2025 annual result was -$1.83, up 3.17% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.38 for Q1 2026 at Enliven Therapeutics, up from -$0.48 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.32 in Q3 2025 to a low of -$3.27 in Q3 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.49 (2025), against an average of -$1.08.
- Across the five-year window, EPS (Weighted Average and Diluted) slumped 341.89% in 2022 and soared 85.66% in 2023, its largest moves.
- Enliven Therapeutics' EPS (Weighted Average and Diluted) stood at -$2.9 in 2022, then jumped by 84.14% to -$0.46 in 2023, then declined by 0.0% to -$0.46 in 2024, then fell by 4.35% to -$0.48 in 2025, then gained by 20.83% to -$0.38 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.38 (Q1 2026), -$0.48 (Q4 2025), and -$0.32 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 0.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -0.61 |
| 10 | Enliven Therapeutics | 2.32 Bn | 2.32 Bn | - | -0.38 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.38 |
| Dec 31, 2025 | -0.48 |
| Sep 30, 2025 | -0.32 |
| Jun 30, 2025 | -0.49 |
| Mar 31, 2025 | -0.57 |
| Dec 31, 2024 | -0.46 |
| Sep 30, 2024 | -0.48 |
| Jun 30, 2024 | -0.41 |
| Mar 31, 2024 | -0.54 |
| Dec 31, 2023 | -0.46 |
| Sep 30, 2023 | -0.51 |
| Jun 30, 2023 | -0.41 |
| Mar 31, 2023 | -0.80 |
| Dec 31, 2022 | -2.90 |
| Sep 30, 2022 | -3.27 |
| Jun 30, 2022 | -2.86 |
| Mar 31, 2022 | -3.01 |
| Dec 31, 2021 | -1.04 |
| Sep 30, 2021 | -0.74 |
| Jun 30, 2021 | -0.74 |